Muscarinic receptor agonists and antagonists

Effects on cancer

    Research output: Chapter in Book/Report/Conference proceedingChapter

    58 Citations (Scopus)

    Abstract

    Many epithelial and endothelial cells express a cholinergic autocrine loop in which acetylcholine acts as a growth factor to stimulate cell growth. Cancers derived from these tissues similarly express a cholinergic autocrine loop and ACh secreted by the cancer or neighboring cells interacts with M3 muscarinic receptors expressed on the cancer cells to stimulate tumor growth. Primary proliferative pathways involve MAPK and Akt activation. The ability of muscarinic agonists to stimulate, and M3 antagonists to inhibit tumor growth has clearly been demonstrated for lung and colon cancer. The ability of muscarinic agonists to stimulate growth has been shown for melanoma, pancreatic, breast, ovarian, prostate and brain cancers, suggesting that M3 antagonists will also inhibit growth of these tumors as well. As yet no clinical trials have proven the efficacy of M3 antagonists as cancer therapeutics, though the widespread clinical use and low toxicity of M3 antagonists support the potential role of these drugs as adjuvants to current cancer therapies.

    Original languageEnglish (US)
    Title of host publicationHandbook of Experimental Pharmacology
    Pages451-468
    Number of pages18
    Volume208
    DOIs
    StatePublished - 2012

    Publication series

    NameHandbook of Experimental Pharmacology
    Volume208
    ISSN (Print)01712004
    ISSN (Electronic)18650325

    Fingerprint

    Muscarinic Agonists
    Muscarinic Antagonists
    Muscarinic Receptors
    Tumors
    Cholinergic Agents
    Neoplasms
    Muscarinic M3 Receptors
    Growth
    Endothelial cells
    Cell growth
    Acetylcholine
    Toxicity
    Brain
    Intercellular Signaling Peptides and Proteins
    Chemical activation
    Cells
    Tissue
    Pancreatic Neoplasms
    Brain Neoplasms
    Pharmaceutical Preparations

    Keywords

    • Acetylcholine
    • Colon cancer
    • Lung cancer
    • M3 muscarinic receptor
    • Muscarinic receptors
    • Therapy

    ASJC Scopus subject areas

    • Pharmacology, Toxicology and Pharmaceutics(all)
    • Biochemistry

    Cite this

    Spindel, E. (2012). Muscarinic receptor agonists and antagonists: Effects on cancer. In Handbook of Experimental Pharmacology (Vol. 208, pp. 451-468). (Handbook of Experimental Pharmacology; Vol. 208). https://doi.org/10.1007/978-3-642-23274-9_19

    Muscarinic receptor agonists and antagonists : Effects on cancer. / Spindel, Eliot.

    Handbook of Experimental Pharmacology. Vol. 208 2012. p. 451-468 (Handbook of Experimental Pharmacology; Vol. 208).

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Spindel, E 2012, Muscarinic receptor agonists and antagonists: Effects on cancer. in Handbook of Experimental Pharmacology. vol. 208, Handbook of Experimental Pharmacology, vol. 208, pp. 451-468. https://doi.org/10.1007/978-3-642-23274-9_19
    Spindel E. Muscarinic receptor agonists and antagonists: Effects on cancer. In Handbook of Experimental Pharmacology. Vol. 208. 2012. p. 451-468. (Handbook of Experimental Pharmacology). https://doi.org/10.1007/978-3-642-23274-9_19
    Spindel, Eliot. / Muscarinic receptor agonists and antagonists : Effects on cancer. Handbook of Experimental Pharmacology. Vol. 208 2012. pp. 451-468 (Handbook of Experimental Pharmacology).
    @inbook{ee02590d377d4112af02f535888d6bfd,
    title = "Muscarinic receptor agonists and antagonists: Effects on cancer",
    abstract = "Many epithelial and endothelial cells express a cholinergic autocrine loop in which acetylcholine acts as a growth factor to stimulate cell growth. Cancers derived from these tissues similarly express a cholinergic autocrine loop and ACh secreted by the cancer or neighboring cells interacts with M3 muscarinic receptors expressed on the cancer cells to stimulate tumor growth. Primary proliferative pathways involve MAPK and Akt activation. The ability of muscarinic agonists to stimulate, and M3 antagonists to inhibit tumor growth has clearly been demonstrated for lung and colon cancer. The ability of muscarinic agonists to stimulate growth has been shown for melanoma, pancreatic, breast, ovarian, prostate and brain cancers, suggesting that M3 antagonists will also inhibit growth of these tumors as well. As yet no clinical trials have proven the efficacy of M3 antagonists as cancer therapeutics, though the widespread clinical use and low toxicity of M3 antagonists support the potential role of these drugs as adjuvants to current cancer therapies.",
    keywords = "Acetylcholine, Colon cancer, Lung cancer, M3 muscarinic receptor, Muscarinic receptors, Therapy",
    author = "Eliot Spindel",
    year = "2012",
    doi = "10.1007/978-3-642-23274-9_19",
    language = "English (US)",
    isbn = "9783642232732",
    volume = "208",
    series = "Handbook of Experimental Pharmacology",
    pages = "451--468",
    booktitle = "Handbook of Experimental Pharmacology",

    }

    TY - CHAP

    T1 - Muscarinic receptor agonists and antagonists

    T2 - Effects on cancer

    AU - Spindel, Eliot

    PY - 2012

    Y1 - 2012

    N2 - Many epithelial and endothelial cells express a cholinergic autocrine loop in which acetylcholine acts as a growth factor to stimulate cell growth. Cancers derived from these tissues similarly express a cholinergic autocrine loop and ACh secreted by the cancer or neighboring cells interacts with M3 muscarinic receptors expressed on the cancer cells to stimulate tumor growth. Primary proliferative pathways involve MAPK and Akt activation. The ability of muscarinic agonists to stimulate, and M3 antagonists to inhibit tumor growth has clearly been demonstrated for lung and colon cancer. The ability of muscarinic agonists to stimulate growth has been shown for melanoma, pancreatic, breast, ovarian, prostate and brain cancers, suggesting that M3 antagonists will also inhibit growth of these tumors as well. As yet no clinical trials have proven the efficacy of M3 antagonists as cancer therapeutics, though the widespread clinical use and low toxicity of M3 antagonists support the potential role of these drugs as adjuvants to current cancer therapies.

    AB - Many epithelial and endothelial cells express a cholinergic autocrine loop in which acetylcholine acts as a growth factor to stimulate cell growth. Cancers derived from these tissues similarly express a cholinergic autocrine loop and ACh secreted by the cancer or neighboring cells interacts with M3 muscarinic receptors expressed on the cancer cells to stimulate tumor growth. Primary proliferative pathways involve MAPK and Akt activation. The ability of muscarinic agonists to stimulate, and M3 antagonists to inhibit tumor growth has clearly been demonstrated for lung and colon cancer. The ability of muscarinic agonists to stimulate growth has been shown for melanoma, pancreatic, breast, ovarian, prostate and brain cancers, suggesting that M3 antagonists will also inhibit growth of these tumors as well. As yet no clinical trials have proven the efficacy of M3 antagonists as cancer therapeutics, though the widespread clinical use and low toxicity of M3 antagonists support the potential role of these drugs as adjuvants to current cancer therapies.

    KW - Acetylcholine

    KW - Colon cancer

    KW - Lung cancer

    KW - M3 muscarinic receptor

    KW - Muscarinic receptors

    KW - Therapy

    UR - http://www.scopus.com/inward/record.url?scp=84856679714&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84856679714&partnerID=8YFLogxK

    U2 - 10.1007/978-3-642-23274-9_19

    DO - 10.1007/978-3-642-23274-9_19

    M3 - Chapter

    SN - 9783642232732

    VL - 208

    T3 - Handbook of Experimental Pharmacology

    SP - 451

    EP - 468

    BT - Handbook of Experimental Pharmacology

    ER -